{"id":5894,"date":"2019-12-04T12:42:47","date_gmt":"2019-12-04T11:42:47","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/vivoryon-therapeutics-ag-schliesst-kapitalerhoehung-in-hoehe-von-43-mio-euro-erfolgreich-ab\/"},"modified":"2020-07-03T09:31:16","modified_gmt":"2020-07-03T07:31:16","slug":"vivoryon-therapeutics-ag-schliesst-kapitalerhoehung-in-hoehe-von-43-mio-euro-erfolgreich-ab","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/vivoryon-therapeutics-ag-schliesst-kapitalerhoehung-in-hoehe-von-43-mio-euro-erfolgreich-ab\/","title":{"rendered":"Vivoryon Therapeutics AG successfully completes a 43 million Euro capital raise"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Vivoryon Therapeutics AG successfully completes a 43 million Euro capital raise<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]Decmber 2019[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Vivoryon Therapeutics AG announced in October 2019 that it has successfully raised capital of approximately 43 million Euro via a rights offering to existing shareholders and a private placement \u00adselected qualified investors in Europe. The proceeds from the offering will be used to fully finance the European Phase 2b clinical study with the Company’s lead product PQ912 for Alzheimer’s Disease, in particular for manufacturing the molecule PQ912 and testing it on approximately 250 patients. The announcement of the results is planned for 2022. The remaining proceeds will be used to prepare and initiate the US Phase 2b clinical trial with PQ912, and to expand Vivoryon\u2019s drug portfolio into further therapeutic areas. The company based in Halle and the IZB in Martinsried has now left the IZB due to its growth strategy and is operating in Munich.
\n[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_single_image image=”5890″ img_size=”155×155″ alignment=”center” style=”vc_box_circle_2″][vc_column_text el_class=”gco-magazine–picture-discription-blank”]Dr. Michael Schaeffer<\/strong>, CBO,
\nDr. Ulrich Dauer<\/strong>, CEO,
\nVivoryon Therapeutics AG[\/vc_column_text][vc_column_text el_class=”gco-magazine-copyright-blank”]<\/p>\n

\u00a9 Vivoryon Therapeutics AG<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n \n
\n Vivoryon Therapeutics N.V. <\/div>\n\n